2 years ago

ImmunONE Secures £2 Million Funding to Expand its 3D Human Lung Model Platform

  • ImmunONE, a UK-based developer of a 3D human lung model to replace animal testing, raised £2 million in funding

  • The round was led by MEIF Proof of Concept & Early Stage Fund, which is managed by Mercia Ventures and part of the Midlands Engine Investment Fund (MEIF), Mercia’s EIS funds and Pioneer Group

  • The company will use the funds to move into new headquarters in Milton Keynes, expand its laboratories in Stevenage, continue research and development, and grow its team

  • Founded by Dr Abigail Martin and Professor Victoria Hutter, ImmunONE has developed a 3D human lung model that assesses the safety of new drugs without animal testing

  • The model allows companies to test the impact of their products on the small airways and inflammation in the lung, providing reliable and reproducible results

  • Since launching two years ago, the company has generated over £1 million in revenue and has around 20 customers globally.

      • ProblemHealthcare

      "Currently, animal testing is used to assess the safety of new drugs, but it's not accurate and invasive."

      Solution

      "ImmunONE develops a 3D human lung model that can assess the safety of new drugs without animal testing, providing more reliable results."

      Covered on